Literature DB >> 7637331

Immunostaining for prostate cancer androgen receptor in paraffin identifies a subset of men with a poor prognosis.

L P Pertschuk1, H Schaeffer, J G Feldman, R J Macchia, Y D Kim, K Eisenberg, L V Braithwaite, C A Axiotis, G Prins, G L Green.   

Abstract

BACKGROUND: Knowledge of androgen receptor (AR) content could help predict hormone response and disease course in prostate cancer. However, determination of AR by biochemical assay is difficult. An immunohistochemical assay (ICA) would solve most difficulties and be especially useful if it could be performed on paraffinized tissue. EXPERIMENTAL
DESIGN: AR was studied in paraffin sections from 90 men for whom endocrine response, survival (except one case), and/or biochemical AR was known. After Ag retrieval in a microwave oven, a polyclonal anti-AR Ab was used with the peroxidase antiperoxidase method. Results were semiquantified using a Histoscore (Hscore) and were correlated with biochemistry, endocrine response, and survival.
RESULTS: Only 15 patients were AR-negative. AR-ICA did not correlate with biochemistry, Gleason score, stage, or ethnicity but did correlate with endocrine response and survival. The average Histoscore was significantly lower in patients with progressive disease (p < 0.05). In a Cox's regression analysis of survival (mean follow-up = 30 months) AR-ICA was a significant predictor (p = 0.015). Risk of death was 2.5 times greater for a patient with a negative assay compared with one with a positive result.
CONCLUSIONS: Our data indicate that AR status by ICA may be a useful predictor of survival and endocrine response in prostate cancer. Further studies are needed to confirm these results because the assay could impact significantly on management.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7637331

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  10 in total

1.  Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer.

Authors:  Liana B Guedes; Carlos L Morais; Fawaz Almutairi; Michael C Haffner; Qizhi Zheng; John T Isaacs; Emmanuel S Antonarakis; Changxue Lu; Harrison Tsai; Jun Luo; Angelo M De Marzo; Tamara L Lotan
Journal:  Clin Cancer Res       Date:  2016-05-10       Impact factor: 12.531

2.  PC3 is a cell line characteristic of prostatic small cell carcinoma.

Authors:  Sheng Tai; Yin Sun; Jill M Squires; Hong Zhang; William K Oh; Chao-Zhao Liang; Jiaoti Huang
Journal:  Prostate       Date:  2011-03-22       Impact factor: 4.104

Review 3.  A role for the androgen-receptor in clinically localized and advanced prostate cancer.

Authors:  James L Mohler
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-04       Impact factor: 4.690

4.  Androgen receptor immunohistochemistry in genitourinary neoplasms.

Authors:  Elizabeth M Williams; John P Higgins; Ankur R Sangoi; Jesse K McKenney; Megan L Troxell
Journal:  Int Urol Nephrol       Date:  2014-09-14       Impact factor: 2.370

5.  Computer based receptogram approach: an objective way of assessing immunohistochemistry of androgen receptor staining and its correlation with hormonal response in metastatic carcinoma of prostate.

Authors:  G Nabi; A Seth; A K Dinda; N P Gupta
Journal:  J Clin Pathol       Date:  2004-02       Impact factor: 3.411

6.  Androgen Receptor Expression in Epithelial and Stromal Cells of Prostatic Carcinoma and Benign Prostatic Hyperplasia.

Authors:  Vanja Filipovski; Katerina Kubelka-Sabit; Dzengis Jasar; Vesna Janevska
Journal:  Open Access Maced J Med Sci       Date:  2017-08-05

7.  The increased expression of fatty acid-binding protein 9 in prostate cancer and its prognostic significance.

Authors:  Majed Saad Al Fayi; Xiaojun Gou; Shiva S Forootan; Waseem Al-Jameel; Zhengzheng Bao; Philip R Rudland; Philip A Cornford; Syed A Hussain; Youqiang Ke
Journal:  Oncotarget       Date:  2016-12-13

Review 8.  Stromal Androgen Receptor in Prostate Cancer Development and Progression.

Authors:  Damien A Leach; Grant Buchanan
Journal:  Cancers (Basel)       Date:  2017-01-22       Impact factor: 6.639

9.  The role of N-cadherin/c-Jun/NDRG1 axis in the progression of prostate cancer.

Authors:  Yongjun Quan; Xiaodong Zhang; William Butler; Zhen Du; Mingdong Wang; Yuexin Liu; Hao Ping
Journal:  Int J Biol Sci       Date:  2021-07-25       Impact factor: 6.580

10.  Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.

Authors:  Lin Jia; Dinglan Wu; Yuliang Wang; Wenxing You; Zhu Wang; Lijia Xiao; Ganhui Cai; Zhenyu Xu; Chang Zou; Fei Wang; Jeremy Yuen-Chun Teoh; Chi-Fai Ng; Shan Yu; Franky L Chan
Journal:  Oncogene       Date:  2018-03-20       Impact factor: 9.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.